Pacific Biosciences of California Stock News

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET Company Participants Todd Friedman - Director, Investor Relations Christian Henry -

Fintel reports that Jackson Square Partners has filed a 13G/A form with the SEC disclosing ownership of 15.01MM shares of Pacific Biosciences of California Inc (PACB).

These cutting-edge biotech companies quickly fell out of favor with investors this week.

The gene sequencing market is ripe for disruption. ILMN suffers from multiple strategic setbacks that will likely impact margins for years.

ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. Click here for an ongoing analysis of the changes made to its portfolio on a quarterly basis.

Here are the five best biotech ETFs to invest in right now.

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been dampened by the displacement of previously-anticipated Sequel IIe sales.

Pacific Biosciences of California (PacBio) PACB shares are trading higher today after the company announced it received orders for 76 Revio systems in the fourth quarter of 2022. The company also issu

Upgrades For Algonquin Power & Utilities Corp (NYSE:AQN), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Algonquin Power showed an EPS of $0.11, compared

PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

MENLO PARK, Calif. , Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in t

PacBio has recently introduced new products that are expected to drive strong growth and improve gross margins over the next four to five years. The new products are the materialization of the company

Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday. Tenax Therapeutics, Inc. (NASDAQ: TENX) jumped 45.7% to close at $0.1351 on Tuesday. Exagen Inc.